Related references
Note: Only part of the references are listed.An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence
Eugen Dhimolea et al.
CANCER CELL (2021)
Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy
Sumaiyah K. Rehman et al.
CELL (2021)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Overcoming Endocrine Resistance in Breast Cancer
Ariella B. Hanker et al.
CANCER CELL (2020)
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Monica Alvarez-Fernandez et al.
CANCER CELL (2020)
Src couples estrogen receptor to the anticipatory unfolded protein response and regulates cancer cell fate under stress
Liqun Yu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Pedram Razavi et al.
NATURE CANCER (2020)
Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing
Dara S. Ross et al.
MODERN PATHOLOGY (2019)
Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations
Liqun Yu et al.
CANCER LETTERS (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
Amelie Darlix et al.
BRITISH JOURNAL OF CANCER (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han et al.
CANCER CELL (2019)
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
Agostina Nardone et al.
BRITISH JOURNAL OF CANCER (2019)
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
Juliet Richman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Rinath Jeselsohn et al.
CANCER CELL (2018)
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Neil O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers
Michelle M. Williams et al.
CELL DEATH & DISEASE (2018)
Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity
S. W. Fanning et al.
NATURE COMMUNICATIONS (2018)
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer
Xiaoling Puyang et al.
CANCER DISCOVERY (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies
Evelyn M. Brosnan et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment
Sophia Mastoraki et al.
CLINICAL CANCER RESEARCH (2018)
Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation
Jessie Peh et al.
CELL CHEMICAL BIOLOGY (2018)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2017)
Generation and characterization of an estrogen receptor alpha-iCre knock-in mouse
Chan Jin Park et al.
GENESIS (2017)
Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance
Kouki Tsuboi et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy
Nicole Rufo et al.
TRENDS IN CANCER (2017)
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
Yuechao Zhao et al.
CANCER RESEARCH (2017)
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani et al.
CLINICAL CANCER RESEARCH (2017)
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
Amir Bahreini et al.
BREAST CANCER RESEARCH (2017)
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
D. J. A. Lobbezoo et al.
ANNALS OF ONCOLOGY (2016)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Anticipatory UPR Activation: A Protective Pathway and Target in Cancer
David J. Shapiro et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
Ameet K. Mishra et al.
ONCOTARGET (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI
Chengjian Mao et al.
SCIENTIFIC REPORTS (2016)
Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues
Natalie S. Shenker et al.
BMC CANCER (2015)
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader
Suzanne E. Wardell et al.
ENDOCRINE-RELATED CANCER (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Christopher D. Hart et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Estrogen receptor a inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression
Neal D. Andruska et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate
Z. Liu et al.
CELL DEATH & DISEASE (2015)
Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer
N. Andruska et al.
ONCOGENE (2015)
Antitumor Activity of a Novel Homodimeric SMAC Mimetic in Ovarian Carcinoma
Laura Gatti et al.
MOLECULAR PHARMACEUTICS (2014)
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
Xi Chen et al.
NATURE (2014)
Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy
Wen Zhou et al.
NATURE REVIEWS CANCER (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer
Edneia A. S. Ramos et al.
BMC CANCER (2010)
Identification and Structure-Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms
Nareshkumar Jain et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines
J. Devon Roll et al.
MOLECULAR CANCER (2008)
Tamoxifen-stimulated growth of breast cancer due to p21 loss
Abde M. Abukhdeir et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Estrogen-regulated gene networks in human breast cancer cells: Involvement of E2F1 in the regulation of cell proliferation
Joshua D. Stender et al.
MOLECULAR ENDOCRINOLOGY (2007)
Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer
Isabel Chu et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production
G Brouckaert et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Tamoxifen: A most unlikely pioneering medicine
VC Jordan
NATURE REVIEWS DRUG DISCOVERY (2003)
NMR Spectroscopy techniques for screening and identifying ligand binding to protein receptors
B Meyer et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor
M Mayer et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2001)
Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer
L Yan et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2001)
Share Paper
